Risk of venous thromboembolism among users of different anti-osteoporosis drugs: a population-based cohort analysis including over 200,000 participants from Spain and the UK

Abstract

VTE risk during AO therapy did not differ by AOM drug use. Our data does not support an increased risk of VTE associated with strontium ranelate use in the community.

The impact of different strategies to handle missing data on both precision and bias in a drug safety study: a multidatabase multinational population-based cohort study

“…A list of Read and International Classification of Primary Care (ICPC) codes for identification of VTE diagnosis recording in CPRD and BIFAP/EpiChron, respectively, is reported elsewhere. 7 Read codes were developed by Dr James Read, and are standard clinical terminology in UK primary care practice.…”

“… Notes: a HR (95% CI) of VTE associated with other oral bisphosphonates, strontium ranelate, teriparatide, and denosumab versus alendronic acid obtained in the CSMI for CPRD and BIFAP was published in a previous article focused on the clinical interpretation of those HRs. 7 En dashes indicate that no estimates were obtained due to small cohort sizes. Abbreviations: AOM, antiosteoporotic medications; BIFAP, Base de datos para la Investigación Farmacoepidemiológica en Atención Primaria; CC, complete case analysis; CPRD, Clinical Practice Research Datalink; CSMI, cross-sectional MI model; HR, hazard ratio; MI, multiple imputation; SERM, selective estrogen receptor modulator; VTE, venous thromboembolism.…”

“… a HR (95% CI) of VTE associated with other oral bisphosphonates, strontium ranelate, teriparatide, and denosumab versus alendronic acid obtained in the CSMI for CPRD and BIFAP was published in a previous article focused on the clinical interpretation of those HRs. 7 En dashes indicate that no estimates were obtained due to small cohort sizes. …”

“…In this study, our aim was to compare the risk estimates observed when applying CC analysis versus MI and give the reader an intuitive understanding and practical overview of the potential issues and limitations of using CC and longitudinal MI by taking the cross-sectional MI as the reference. As a part of a cohort study on the risk of venous thromboembolism (VTE) associated with the use of different antiosteoporotic medications (AOM), 7 we explored the issues of missing data and compared different methods using data from three different EMR databases from Spain and the UK. Our secondary aim was to describe a step-by-step approach for setting up and conducting MIs in drug safety studies using EMR data and to list practical challenges faced during the MI process.…”

Association between glycemic control and risk of venous thromboembolism in diabetic patients: A nested case-control study

“…We de ned cases as patients with a rst-time recording of VTE during the study period, who received at least one prescription for an antithrombotic drug within 7 days prior until 90 days after the VTE, [5,34,35] including antiplatelet drugs, vitamin K antagonists, heparins, direct factor Xa inhibitors, direct thrombin inhibitors, brinolytic enzymes, or the synthetic penta-saccharide factor Xa inhibitor fondaparinux. The index date for each case was the date of the rst recorded VTE.…”